Phase 3 ALTA-1L compared brigatinib to crizotinib in patients with advanced NSCLC, who did not previously receive an ALK inhibitor, and demonstrated a higher median PFS and ORR for brigatinib. Here, ALK is linked to non-small cell lung carcinoma.